INC Files for IPO
INC Research, a global Phase I to IV contract research organization, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) related to a proposed initial public offering of its common stock.
INC Research, a global Phase I to IV contract research organization, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) related to a proposed initial public offering of its common stock. The number of shares to be offered by INC Research and its stockholders and the price range for the offering have not yet been determined. The Company has applied to list its common stock on The NASDAQ Global Market under the ticker symbol “INCR.”
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
